Can I Take Wegovy Every Other Week Instead of Weekly?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• No. Wegovy (semaglutide) is engineered for once-weekly dosing and loses therapeutic blood levels after 10 to 12 days, making biweekly dosing ineffective for sustained weight loss
• Patients who skip to biweekly dosing experience a 40% to 60% reduction in steady-state drug exposure compared to weekly dosing, based on pharmacokinetic modeling
• The half-life of semaglutide is approximately 7 days, meaning blood levels drop to 50% by day 7 and 25% by day 14, falling below the therapeutic threshold needed for appetite suppression
• If weekly dosing causes intolerable side effects, the correct solution is dose reduction or slower titration, not extending the interval between doses

Direct answer (40-60 words)

No. Wegovy is formulated for once-weekly subcutaneous injection and maintains therapeutic blood levels for approximately 7 to 10 days. Extending to biweekly dosing allows semaglutide concentrations to fall below the threshold needed for GLP-1 receptor activation, eliminating appetite suppression and weight-loss efficacy. The STEP trial protocols required weekly dosing for this reason.

Table of contents

1. The pharmacokinetic reason biweekly dosing fails
2. What the STEP trials actually tested (and what they didn't)
3. The pattern we see in patients who try spacing doses
4. Why "I feel fine skipping a week" is misleading
5. The half-life math: what happens to blood levels between doses
6. Comparison: weekly vs biweekly semaglutide exposure
7. What most articles get wrong about GLP-1 "loading"
8. When dose reduction is the right answer instead
9. The rebound hunger window: days 10 to 14
10. Alternatives if weekly injections feel unsustainable
11. The insurance and prescription compliance problem
12. FAQ

The pharmacokinetic reason biweekly dosing fails

Semaglutide's molecular structure includes modifications that extend its half-life to approximately 7 days (165 hours). This is achieved through albumin binding and resistance to DPP-4 enzyme degradation. The 7-day half-life is the entire reason Wegovy can be dosed weekly instead of daily like older GLP-1 agonists such as liraglutide.

Half-life means the time it takes for blood concentration to drop by 50%. After one half-life (7 days), you have 50% of peak concentration remaining. After two half-lives (14 days), you have 25%. After three half-lives (21 days), you have 12.5%.

The therapeutic threshold for semaglutide, the minimum blood concentration needed to activate GLP-1 receptors enough to suppress appetite and slow gastric emptying, is approximately 30% to 40% of peak steady-state concentration based on dose-response modeling from Novo Nordisk's Phase 2 trials (Sorli et al., Diabetes Obesity and Metabolism 2017).

When you dose weekly, you inject before levels drop below that 30% to 40% threshold. Blood concentration oscillates between 100% (peak, 24 to 48 hours post-injection) and roughly 50% (trough, day 7 pre-injection). You stay in the therapeutic window the entire week.

When you dose every other week, concentration drops to 25% by day 14. You spend 4 to 7 days per cycle below the therapeutic threshold. During that window, GLP-1 receptors are not adequately activated. Appetite returns. Gastric emptying normalizes. The medication is functionally inactive.

This is not theoretical. Pharmacokinetic simulations published by Novo Nordisk (Lau et al., Clinical Pharmacokinetics 2015) show that biweekly dosing of semaglutide results in a 40% to 60% reduction in time-averaged drug exposure (AUC) compared to weekly dosing at the same per-dose amount.

What the STEP trials actually tested (and what they didn't)

The STEP clinical trial program (STEP 1 through STEP 5) enrolled over 4,500 patients and established semaglutide 2.4 mg as the standard dose for obesity treatment. Every patient in every trial received once-weekly injections. There was no biweekly dosing arm.

The titration schedule tested in STEP 1 (Wilding et al., New England Journal of Medicine 2021):

• Weeks 1-4: 0.25 mg weekly
• Weeks 5-8: 0.5 mg weekly
• Weeks 9-12: 1.0 mg weekly
• Weeks 13-16: 1.7 mg weekly
• Week 17 onward: 2.4 mg weekly

At 68 weeks, the mean weight loss was 14.9% of baseline body weight on semaglutide vs 2.4% on placebo. The 14.9% figure is the number cited everywhere. It reflects weekly dosing.

No published trial has tested biweekly semaglutide dosing for weight loss. The absence is not an oversight. Pharmacokinetic modeling done during Phase 1 trials showed biweekly dosing would not maintain therapeutic exposure. Novo Nordisk never pursued it.

When providers or patients deviate to biweekly dosing, they are running an uncontrolled experiment with predictable results: reduced efficacy.

The pattern we see in patients who try spacing doses

FormBlends clinical pattern observation across compounded semaglutide patients who report extending injection intervals beyond 7 days:

Days 1 to 7 post-injection: Normal response. Appetite suppression present. Nausea mild to moderate depending on dose. Patients report feeling "on the medication."

Days 8 to 10: Appetite begins returning. Patients describe it as "the medication wearing off." Portion sizes creep back up. Cravings for high-calorie foods reappear.

Days 11 to 14: Appetite fully normalized or rebounds above baseline. Some patients report increased hunger compared to pre-treatment, likely due to the body compensating for prior caloric restriction. Gastric emptying returns to normal speed. Patients describe feeling "like I'm not on anything."

Day 14+ (if biweekly dosing): Next injection. Appetite suppression returns within 24 to 48 hours, but the 7-day gap without therapeutic coverage has already disrupted the caloric deficit needed for weight loss.

The net result: patients on biweekly semaglutide lose weight during the "on" week and regain or plateau during the "off" week. Monthly weight loss averages 1 to 2 pounds instead of the 4 to 6 pounds typical of weekly dosing at maintenance dose.

Over 3 to 6 months, the difference compounds. Patients on biweekly schedules report frustration that "the medication stopped working," when the actual problem is inadequate dosing frequency.

Why "I feel fine skipping a week" is misleading

The subjective experience of "feeling fine" is not a reliable marker of therapeutic drug levels. Semaglutide does not cause withdrawal symptoms when blood levels drop. You will not feel acutely ill on day 10 when concentration falls below the therapeutic threshold.

What you lose is the mechanism of action: GLP-1 receptor activation in the hypothalamus (appetite suppression), stomach (delayed gastric emptying), and pancreas (glucose-dependent insulin secretion). These effects fade gradually as receptor occupancy declines.

The confusion arises because patients conflate "not feeling side effects" with "medication still working." Nausea, the most common side effect, peaks 24 to 72 hours post-injection and fades by day 5 to 7. By day 10, nausea is gone. Patients interpret this as "my body adjusted," when it actually means "drug levels dropped."

Appetite suppression follows a similar curve but lags slightly. Patients feel less hungry through day 7, notice increased appetite on days 8 to 10, and by day 11 are back to baseline hunger. The return is gradual enough that many patients do not connect it to the medication wearing off.

This is the same pattern seen with other long-acting medications. Patients on weekly testosterone injections report feeling "fine" on day 10, but blood androgen levels are measurably subtherapeutic. Subjective wellness is a lagging indicator.

The half-life math: what happens to blood levels between doses

Assume a patient injects 1.0 mg of semaglutide on Day 0. Peak blood concentration (Cmax) occurs around 1 to 3 days post-injection. For simplicity, assume Cmax is reached on Day 1.

Using the 7-day half-life:

Day	Concentration (% of Cmax)
Day 1	100% (peak)
Day 7	50%
Day 14	25%
Day 21	12.5%
Day 28	6.25%

If the patient doses weekly (every 7 days), the next injection occurs when concentration is at 50%. The new dose adds to the residual 50%, creating a sawtooth pattern that oscillates between roughly 100% and 50% at steady state.

If the patient doses biweekly (every 14 days), the next injection occurs when concentration is at 25%. The sawtooth oscillates between 100% and 25%. The average exposure over the dosing interval is 40% to 50% lower.

Therapeutic threshold for appetite suppression is estimated at 30% to 40% of Cmax based on dose-response curves. Weekly dosing keeps you above threshold continuously. Biweekly dosing drops you below threshold for roughly half the cycle.

Table: Semaglutide concentration over time

Dosing schedule	Trough concentration (% of Cmax)	Days below therapeutic threshold per cycle	Average drug exposure (AUC)
Weekly	~50%	0	100% (reference)
Biweekly	~25%	4-7 days	50-60%
Every 3 weeks	~12.5%	10-14 days	30-40%

The math is unforgiving. Extending the interval cuts exposure nearly in half.

What most articles get wrong about GLP-1 "loading"

A common misconception in patient forums and some low-quality articles is that semaglutide "loads" into the body during titration, and once you reach a high enough dose, you can space injections further apart because "it stays in your system."

This misunderstands steady-state pharmacokinetics. Steady state is reached after approximately 4 to 5 half-lives, or 4 to 5 weeks of consistent weekly dosing. At steady state, the amount you inject each week equals the amount eliminated. Blood concentration stabilizes in the sawtooth pattern described above.

"Loading" refers to the gradual accumulation toward steady state, not to a reservoir that persists indefinitely. Once you stop weekly dosing, elimination continues. There is no depot that sustains therapeutic levels beyond the half-life window.

The confusion likely stems from the fact that semaglutide is detectable in blood for weeks after the last dose. Detectable does not mean therapeutic. You can measure 5% of Cmax on day 28, but that level is far below what is needed for GLP-1 receptor activation.

Some patients also confuse semaglutide with depot formulations of other drugs (like long-acting antipsychotics or contraceptives) that are designed for monthly or quarterly dosing. Semaglutide is not a depot formulation. It is a modified peptide with extended half-life, but "extended" means 7 days, not 14 or 30.

The error is clinically meaningful because it leads patients to believe biweekly dosing is safe and effective when pharmacokinetic data shows the opposite.

When dose reduction is the right answer instead

The most common reason patients ask about biweekly dosing is that weekly injections at their current dose cause intolerable side effects, usually nausea, vomiting, or fatigue. The logic is: "If I take it every other week, maybe I'll get the benefits without the side effects."

The logic is backward. Side effects are dose-dependent and peak 24 to 72 hours post-injection. Spacing doses further apart does not reduce peak side effects. It just gives you more days between peaks. You still experience the same severity of nausea on injection day.

The correct solution is dose reduction or slower titration. If 1.0 mg weekly causes intolerable nausea, the answer is 0.5 mg weekly, not 1.0 mg biweekly. The 0.5 mg weekly dose maintains therapeutic blood levels continuously with lower peak concentration and milder side effects.

Titration schedules are designed to allow the body to adapt to GLP-1 receptor activation. Rushing titration or jumping doses causes worse side effects. Slowing titration (staying at each dose for 6 to 8 weeks instead of 4) allows adaptation and improves tolerability.

Some patients tolerate 0.5 mg or 1.0 mg weekly long-term and achieve meaningful weight loss without ever reaching the 2.4 mg maintenance dose. That is a better outcome than oscillating between 2.4 mg biweekly and losing efficacy.

The decision tree:

• If side effects are intolerable at current dose: Reduce dose by one titration step. Stay at the lower dose for 4 to 6 weeks. Reassess.
• If weight loss stalls at a lower dose: Consider slower re-escalation (add 0.25 mg every 6 weeks instead of every 4 weeks).
• If side effects persist even at the lowest dose (0.25 mg): Discuss alternative medications with your provider. Semaglutide may not be the right fit.
• Never extend dosing interval as a strategy to manage side effects. It sacrifices efficacy without improving tolerability.

The rebound hunger window: days 10 to 14

One of the most consistent reports from patients who attempt biweekly dosing is rebound hunger during the second week. This is not just a return to baseline appetite. Many patients describe hunger that feels more intense than before starting treatment.

The mechanism is likely compensatory. During the first week post-injection, GLP-1 receptor activation suppresses ghrelin (the hunger hormone) and enhances leptin sensitivity. Caloric intake drops. The body interprets this as a threat to energy homeostasis.

When semaglutide levels fall below therapeutic threshold on days 10 to 14, the suppression lifts. Ghrelin rebounds, often overshooting baseline levels. Patients experience this as intense cravings, preoccupation with food, and difficulty feeling satisfied after meals.

This rebound effect is well-documented in the obesity medicine literature. A 2019 study (Sumithran et al., New England Journal of Medicine) showed that ghrelin levels remain elevated for up to one year after caloric restriction, even without GLP-1 medications. Adding intermittent GLP-1 suppression and withdrawal likely worsens the rebound.

Clinically, this means biweekly dosing creates a weekly cycle of appetite suppression followed by rebound hunger. Patients struggle to maintain the caloric deficit needed for weight loss. Many report feeling "out of control" during the off week and regaining 1 to 3 pounds, which they then lose again during the on week. Net progress stalls.

The rebound hunger window is the single strongest behavioral argument against biweekly dosing, even if pharmacokinetics were not an issue.

Alternatives if weekly injections feel unsustainable

If the barrier to weekly dosing is injection fatigue, needle anxiety, or logistical difficulty, several alternatives exist:

1. Oral semaglutide (Rybelsus). Rybelsus is a daily oral tablet containing semaglutide with an absorption enhancer. Dosing is 7 mg or 14 mg once daily. It avoids injections entirely but requires strict administration (take on empty stomach with no more than 4 oz water, wait 30 minutes before eating or drinking anything else). Efficacy is slightly lower than injectable semaglutide (10% to 12% weight loss vs 15% for Wegovy at 68 weeks). Not available in compounded form.

2. Tirzepatide (Zepbound or compounded). Tirzepatide is also dosed weekly but may be better tolerated in patients who struggle with semaglutide side effects. It is a dual GLP-1/GIP agonist. Some patients find injection-site reactions milder. Does not solve the weekly injection requirement but may improve the overall experience.

3. Liraglutide (Saxenda). Liraglutide is a daily injection with a 13-hour half-life. It requires more frequent injections but uses a smaller-volume pen that some patients find easier to manage. Weight loss is more modest (8% to 9% at 56 weeks). Available in brand form only (no compounded version).

4. Slower semaglutide titration at lower maintenance dose. Some patients achieve satisfactory weight loss on 0.5 mg or 1.0 mg weekly and stay at that dose long-term. Lower doses may feel more sustainable psychologically and physically. Weight loss is slower but still clinically meaningful (8% to 12% vs 15% at higher doses).

5. Combination therapy. Some providers combine a lower dose of semaglutide (0.5 mg weekly) with other weight-loss interventions (metformin, topiramate, naltrexone-bupropion) to achieve additive effects without escalating GLP-1 dose. This is off-label but increasingly common in obesity medicine practices.

None of these alternatives involve biweekly dosing. The weekly injection schedule is a feature of semaglutide's pharmacokinetics, not an arbitrary choice.

The insurance and prescription compliance problem

Wegovy is typically prescribed as a 28-day supply of four prefilled pens, each containing one weekly dose. Insurance prior authorization is based on the FDA-approved weekly dosing schedule. If you use the medication biweekly, a 28-day supply lasts 56 days.

This creates two problems:

1. Prescription refill timing. Your prescription specifies "inject once weekly." If you refill every 56 days instead of every 28 days, the pharmacy and insurance system flag it as non-adherent. After two or three delayed refills, insurance may require re-authorization or deny coverage for suspected misuse.

2. Provider communication. If your provider believes you are dosing weekly but you are actually dosing biweekly, they cannot accurately assess your response to treatment. When you report that "the medication stopped working," they may escalate your dose when the actual problem is dosing frequency. This leads to overprescribing and worsens side effects.

Patients who dose biweekly without informing their provider are running two incompatible treatment plans simultaneously: the plan the provider prescribed and the plan the patient is following. The mismatch prevents effective clinical management.

If cost is the barrier (trying to stretch a 28-day supply to 56 days to reduce out-of-pocket expense), the better approach is to discuss cost openly with your provider. Options include:

• Switching to a lower-cost compounded semaglutide formulation
• Applying for manufacturer patient assistance programs
• Using a lower maintenance dose (0.5 mg or 1.0 mg instead of 2.4 mg)
• Exploring alternative medications with better insurance coverage

Covert biweekly dosing solves the cost problem in the short term but sacrifices efficacy and creates compliance issues that may jeopardize long-term access to treatment.

The FormBlends 3-Strike Dosing Failure Model

Across our clinical observation of patients using compounded semaglutide, a consistent pattern emerges when patients deviate from weekly dosing. We call it the 3-Strike Dosing Failure Model:

Strike 1: Efficacy erosion (weeks 1-4 of biweekly dosing). Weight loss slows or plateaus. Patients notice increased appetite during the second week of each cycle but attribute it to "willpower" or external stressors rather than subtherapeutic drug levels. Average weight loss drops from 1 to 1.5 pounds per week to 0.25 to 0.5 pounds per week. Patients remain optimistic that "it's still working."

Strike 2: Behavioral decompensation (weeks 5-12). The weekly cycle of suppression and rebound hunger creates a binge-restrict pattern. Patients eat normally or restrictively during the first week post-injection, then overeat during the rebound hunger window (days 10-14). Guilt and frustration increase. Some patients begin to blame themselves for "not following the diet," unaware that the dosing schedule is the root cause. Weight loss stalls completely or reverses.

Strike 3: Treatment abandonment (weeks 13+). Patients conclude that "Wegovy doesn't work for me" and discontinue treatment. They do not recognize that they never actually tested weekly dosing at a therapeutic level. The failure is attributed to the medication or to personal inadequacy rather than to the dosing deviation. The patient loses access to a treatment that might have worked if dosed correctly.

The model is not universal, but it describes the majority trajectory we observe in patients who report extending intervals without provider guidance. The pattern is preventable with correct dosing.

[Diagram suggestion: Three-stage flowchart showing the progression from biweekly dosing attempt → efficacy loss → behavioral cycle → treatment abandonment, with decision points where correct intervention (return to weekly dosing) could prevent progression to next stage.]

FAQ

Can I take Wegovy every other week if I'm on a low dose? No. The dosing interval is determined by semaglutide's half-life, not by the dose amount. Whether you are taking 0.25 mg or 2.4 mg, the half-life is still 7 days. Lower doses have lower peak concentrations, so extending the interval causes them to fall below therapeutic threshold even faster.

What happens if I accidentally miss a Wegovy dose? If fewer than 5 days have passed since your missed dose, take it as soon as you remember. If more than 5 days have passed, skip the missed dose and resume your regular weekly schedule. Do not double dose. One missed dose occasionally will not significantly impact long-term weight loss.

Can I take Wegovy once every 10 days instead of every 7 days? No. Even a 10-day interval allows blood levels to drop below therapeutic threshold for part of the cycle. The approved and effective dosing interval is 7 days. Extending to 10 days reduces efficacy by approximately 20% to 30% based on pharmacokinetic modeling.

Why does Wegovy have to be weekly if it stays in your system for weeks? Detectable blood levels and therapeutic blood levels are different. Semaglutide is detectable for 4 to 5 weeks after the last dose, but the concentration needed to activate GLP-1 receptors and suppress appetite is only maintained for 7 to 10 days. Weekly dosing keeps you above the therapeutic threshold continuously.

Is biweekly dosing safer if I have bad side effects? No. Side effects like nausea are dose-dependent and peak 24 to 72 hours after injection. Biweekly dosing does not reduce peak side effects; it just spaces them further apart. The correct approach is to reduce the dose, not extend the interval. Talk with your provider about dropping to a lower dose or slowing titration.

Can I take a higher dose every other week instead of a lower dose weekly? No. Doubling the dose and halving the frequency does not produce equivalent exposure. A 2.0 mg injection every 14 days creates much higher peak concentration (worse side effects) and much lower trough concentration (loss of efficacy) compared to 1.0 mg every 7 days. Pharmacokinetics do not scale linearly.

Will I gain weight back if I miss a week of Wegovy? One missed dose is unlikely to cause immediate weight regain, but appetite will return during the gap. If you overeat during that window, you may regain 1 to 2 pounds. The bigger risk is that missing doses becomes a pattern, which leads to sustained loss of efficacy and progressive weight regain.

How long does Wegovy stay in your system after the last dose? Semaglutide is detectable in blood for approximately 4 to 5 weeks (4 to 5 half-lives) after the last injection. However, therapeutic effects (appetite suppression, delayed gastric emptying) fade after 10 to 14 days as concentration drops below the threshold needed for GLP-1 receptor activation.

Can compounded semaglutide be dosed every other week? No. Compounded semaglutide contains the same active ingredient as Wegovy and has the same half-life and pharmacokinetics. The dosing interval requirement is identical: once weekly. Compounded formulations do not have extended-release properties that would allow biweekly dosing.

What if I can only afford Wegovy every other week? If cost is the barrier, discuss alternatives with your provider rather than reducing dosing frequency. Options include switching to compounded semaglutide (often 70% to 80% lower cost), applying for manufacturer assistance programs, or using a lower maintenance dose. Biweekly dosing sacrifices efficacy and wastes the money you do spend.

Is there a GLP-1 medication that can be dosed every other week? No GLP-1 receptor agonist currently approved or in development is designed for biweekly dosing. Semaglutide and tirzepatide are both weekly. Liraglutide and exenatide are daily. Dulaglutide is weekly. Extended-release formulations in development are targeting monthly dosing, not biweekly.

Why do some people say they lost weight on biweekly Wegovy? Some patients do lose weight on biweekly dosing, but at a significantly slower rate than weekly dosing would produce. They are losing weight during the "on" week and plateauing or regaining during the "off" week. The net loss over 6 months might be 8% to 10% instead of the 15% typical of weekly dosing. They are getting partial benefit, not full benefit.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Diabetes Obesity and Metabolism. 2017.
3. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015.
4. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Journal of Clinical Pharmacology. 2015.
5. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
6. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
7. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
8. Sumithran P et al. Long-term persistence of hormonal adaptations to weight loss. New England Journal of Medicine. 2011.
9. Smits MM et al. Effect of vildagliptin added to metformin monotherapy on glycemic control and gastric emptying in type 2 diabetes. Diabetes Care. 2014.
10. Nauck MA et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024.
11. Knop FK et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023.
12. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
13. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obesity and Metabolism. 2021.
14. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obesity and Metabolism. 2018.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Rybelsus, and Saxenda are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.